Management of Recurrent Vulvovaginal Candidiasis (RVVC) With Maintenance Suppressive Weekly Fluconazole: A Multicenter Study.

J. D. SOBEL, S. HILLIER, L. SMOLENSKI , M. MARTENS , P. DANNA , H. PANZER, RVVC Group, and the RVVC Group

Abstract: 

Background: RVVC occurs in 5-8% of premenopausal women and is multifactorial in origin. No proven safe therapeutic modalities exist. Methods: A multicenter prospective randomized, controlled, double-blind study comparing Fluconazole 150 mg (FLU) versus placebo (P) both administered once weekly for 6 months and then followed off therapy for further 6 months. Results: 494 adult females with RVVC ( 4 episodes/previous 12 m) and acute VVC received 3 doses of FLU to achieve remission (Induction Phase). 379 patients responding to open label fluconazole were randomized to FLU (189) and P (190). Baseline mycology at enrollment, 94.4% C. albicans, 3.1% C. glabrata. At the completion of 6m maintenance, 128/141 (90.8%) on FLU remained cured versus 51/142 (35.9%) on placebo (p
2002

abstract No: 

NULL

Full conference title: 

42nd Interscience Conference on Antimicrobial Agents and Chemotherapy
    • ICAAC 42nd